Seaport and Hemab target $180m IPOs as biotech listings accumulate
Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax…
-
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU)…
-
FDA seeks permanent future for rare pediatric priority review vouchers
The US Food and Drug Administration (FDA) is seeking to permanently authorise the rare pediatric disease priority review voucher (PRV)…
-
Pharma industry laments Trump’s tariff on branded drugs
The pharmaceutical industry has widely criticised the US administration’s decision to impose a 100% tariff on branded drugs imported into…
-
Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s…
-
Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first…
-
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to $7.8bn, solidifying the drugmaker’s status as…
-
Podcast: European biotech rallies against US and China powerhouses
As Lisbon played host to BIO Europe Spring, an annual conference that brings together professionals across the global biotech sector,…
-
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
The US Food and Drug Administration (FDA) has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) in leukocyte adhesion deficiency type I…